| E&P Financial Group Limited (EP1) ORDINARY FULLY PAID |
Financials |
- |
Update - Notification of buy-back - EP1
|
26 Nov 2024 8:47AM |
$0.510 |
$0.515 |
risen by
0.98%
|
|
| Sarytogan Graphite Limited (SGA) ORDINARY FULLY PAID |
Materials |
$8 |
Becoming a substantial holder
|
26 Nov 2024 8:47AM |
$0.081 |
$0.044 |
fallen by
45.68%
|
|
| NobleOak Life Limited (NOL) ORDINARY FULLY PAID |
Financials |
$126 |
Board Renewal
|
26 Nov 2024 8:47AM |
$1.675 |
$1.355 |
fallen by
19.10%
|
|
| NobleOak Life Limited (NOL) ORDINARY FULLY PAID |
Financials |
$126 |
2024 AGM - Presentation
|
26 Nov 2024 8:45AM |
$1.675 |
$1.355 |
fallen by
19.10%
|
|
| Aroa Biosurgery Limited (ARX) ORDINARY FULLY PAID |
Health Care |
$152 |
Aroa Half Year Results Presentation
|
26 Nov 2024 8:45AM |
$0.650 |
$0.440 |
fallen by
32.31%
|
|
ARX - Price-sensitive ASX Announcement
Full Release
Key Points
- Total addressable market exceeding $3 billion.
- Total revenue of NZ$39.2 million.
- Product gross margins of 86%.
- Significant growth in Myriad and Ovitex sales.
- Commitment to innovation in soft tissue regeneration.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Carlton Investments Limited (CIN) ORDINARY FULLY PAID |
Financials |
$885 |
Daily share buy-back notice - Appendix 3E
|
26 Nov 2024 8:45AM |
$30.500 |
$33.500 |
risen by
9.84%
|
|
| Orion Minerals Ltd (ORN) ORDINARY FULLY PAID |
Materials |
$82 |
Change of Director's Interest Notice - Mpofu
|
26 Nov 2024 8:44AM |
$0.015 |
$0.012 |
fallen by
20%
|
|
| Orion Minerals Ltd (ORN) ORDINARY FULLY PAID |
Materials |
$82 |
Change of Director's Interest Notice - Lennox
|
26 Nov 2024 8:43AM |
$0.015 |
$0.012 |
fallen by
20%
|
|
| Anagenics Limited (AN1) ORDINARY FULLY PAID |
Consumer Staple |
$3 |
2024 AGM Presentation 261124
|
26 Nov 2024 8:43AM |
$0.008 |
$0.007 |
fallen by
12.50%
|
|
| EML Payments Limited (EML) ORDINARY FULLY PAID |
Financials |
$363 |
EML 2.0 Strategy Plan Investor Presentation & Trading Update
|
26 Nov 2024 8:43AM |
$0.685 |
$0.950 |
risen by
38.69%
|
|
EML - Price-sensitive ASX Announcement
Full Release
Key Points
- Trading for Q1 FY25 is in line with management expectations.
- GDV increased by 7% to A$5,857 million.
- Revenue increased by 12% to A$48.8 million.
- Underlying EBITDA guidance for FY25 reaffirmed at A$54-60 million.
- EML Payments operates globally in Australia, the UK, Europe, and the US.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Orion Minerals Ltd (ORN) ORDINARY FULLY PAID |
Materials |
$82 |
Change of Director's Interest Notice - Gomwe
|
26 Nov 2024 8:42AM |
$0.015 |
$0.012 |
fallen by
20%
|
|
| FleetPartners Group Limited (FPR) ORDINARY FULLY PAID |
Financials |
$692 |
Update - Notification of buy-back - FPR
|
26 Nov 2024 8:40AM |
$3.230 |
$3.080 |
fallen by
4.64%
|
|
| Amotiv Limited (AOV) ORDINARY FULLY PAID |
Consumer Discretionary |
$1,064 |
Update - Notification of buy-back - AOV
|
26 Nov 2024 8:40AM |
$10.200 |
$7.800 |
fallen by
23.53%
|
|
| Aroa Biosurgery Limited (ARX) ORDINARY FULLY PAID |
Health Care |
$152 |
Aroa Biosurgery Half Yearly Results H1 FY25
|
26 Nov 2024 8:39AM |
$0.650 |
$0.440 |
fallen by
32.31%
|
|
ARX - Price-sensitive ASX Announcement
Full Release
Key Points
- Product sales grew by 25% to NZ$39.1 million.
- Sales of Myriad products increased by 45% to NZ$14.8 million.
- Total reported revenue grew by 23% to NZ$39.2 million.
- Normalised EBITDA loss decreased to NZ$1.5 million from NZ$2.7 million.
- Company remains debt-free with a cash balance of NZ$21.6 million.
- Full-year FY25 guidance maintained at NZ$80-87 million total revenue.
- AROA's Myriad active accounts grew to 265, up from 218.
- Eight peer-reviewed studies published during the reporting period.
- Progressing commercialisation of the Enivo platform.
- Successful completion of the annual DEKRA audit.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Aroa Biosurgery Limited (ARX) ORDINARY FULLY PAID |
Health Care |
$152 |
Appendix 4D and Half Year Report
|
26 Nov 2024 8:38AM |
$0.650 |
$0.440 |
fallen by
32.31%
|
|
ARX - Price-sensitive ASX Announcement
Full Release
Key Points
- Product sales grew by 25% compared to H1 FY24.
- Aroa expects positive cash flow in H2 FY25.
- Clinical evidence supporting ECM products is being expanded.
- Loss before tax decreased by 53% compared to the previous period.
- Net cash outflow from operating activities reduced by 33%.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Recce Pharmaceuticals Ltd (RCE) ORDINARY FULLY PAID |
Health Care |
$77 |
Australia Patent Granted for RECCE Anti-Infectives
|
26 Nov 2024 8:37AM |
$0.470 |
$0.295 |
fallen by
37.23%
|
|
RCE - Price-sensitive ASX Announcement
Full Release
Key Points
- Patent Family 3 granted by Australian Patent Office.
- RECCE® 327 and RECCE® 529 patents now protected until 2037.
- Covers manufacturing processes and treatment uses for infections.
- Protection extends across all major pharmaceutical markets.
- CEO highlights potential in addressing viral threats.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| EML Payments Limited (EML) ORDINARY FULLY PAID |
Financials |
$363 |
Chairman and CEO Address - 2024 AGM
|
26 Nov 2024 8:36AM |
$0.685 |
$0.950 |
risen by
38.69%
|
|
EML - Price-sensitive ASX Announcement
Full Release
Key Points
- The 2024 AGM showcased EML's progress and future growth strategies.
- EML Payments Limited aims for double-digit transaction revenue growth by FY27.
- Significant improvements in financial performance were reported for FY24.
- The company has addressed historical challenges and strengthened its foundation.
- Strategic initiatives include nurturing customer relationships and entering new markets.
- Investment in technology is prioritized for operational efficiency.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| INOVIQ Ltd (IIQ) ORDINARY FULLY PAID |
Health Care |
$45 |
INOVIQ receives $1m RDTI refund
|
26 Nov 2024 8:36AM |
$0.440 |
$0.400 |
fallen by
9.09%
|
|
IIQ - Price-sensitive ASX Announcement
Full Release
Key Points
- INOVIQ receives $1.018m R&D Tax Incentive refund.
- Refund relates to FY24 R&D activities.
- R&D Tax Incentive provides 43.5% refundable tax offset.
- INOVIQ incurred $2.7m on eligible R&D activities.
- Company developing next-generation diagnostics and therapeutics for cancer.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Native Mineral Resources Holdings Limited (NMR) ORDINARY FULLY PAID |
Materials |
$137 |
NMR accelerates plans to re-start production at QLD project
|
26 Nov 2024 8:34AM |
$0.037 |
$0.155 |
risen by
318.92%
|
|
NMR - Price-sensitive ASX Announcement
Full Release
Key Points
- NMR is accelerating plans for potential gold production from recently acquired BlackJack and Far Fanning gold deposits in Queensland.
- The BlackJack processing plant can be refurbished allowing for production before end of CY2025.
- Diamond drilling program at Far Fanning set to commence soon to upgrade the Inferred Mineral Resource Estimate.
- Sampling of stockpiles and waste ore at Far Fanning continues, with many samples returning grades above 0.5g/t Au.
- NMR plans to conduct metallurgical testing on stockpiled material for onsite processing.
- Engagement of specialized contractors has begun for the plant's inspection and refurbishment.
- Remediation works of administration buildings and site security measures have been initiated.
- Managing Director Blake Cannavo has extensive experience in mining and construction sectors.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Kogan.com Ltd (KGN) ORDINARY FULLY PAID |
Consumer Discretionary |
$398 |
Update - Notification of buy-back - KGN
|
26 Nov 2024 8:31AM |
$4.970 |
$4.000 |
fallen by
19.52%
|
|
| Viva Leisure Limited (VVA) ORDINARY FULLY PAID |
Consumer Discretionary |
$131 |
Update - Notification of buy-back - VVA
|
26 Nov 2024 8:31AM |
$1.360 |
$1.290 |
fallen by
5.15%
|
|
| Polymetals Resources Ltd (POL) ORDINARY FULLY PAID |
Materials |
$207 |
Endeavor Exploration update
|
26 Nov 2024 8:31AM |
$0.700 |
$0.830 |
risen by
18.57%
|
|
POL - Price-sensitive ASX Announcement
Full Release
Key Points
- Carpark Prospect EM Conductor Plate drilling to commence during January 2025.
- New high-ranking prospects identified within Exploration & Mining Licence areas.
- Regional exploration to kick off in Q1 CY2025 starting with 18km of IP survey lines.
- Polymetals has identified 9 near mine exploration targets.
- Carpark is a potential southern extension to the Endeavor orebody.
- Twelve RC/core holes over Carpark have intercepted broad zones of mineralisation.
- Next phase of drilling at Carpark will test for a massive sulphide body.
- The company plans to ramp up exploration activities over its entire Endeavor Project tenure.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Arovella Therapeutics Limited (ALA) ORDINARY FULLY PAID |
Health Care |
$85 |
Notification regarding unquoted securities - ALA
|
26 Nov 2024 8:29AM |
$0.190 |
$0.072 |
fallen by
62.11%
|
|
| L1 Long Short Fund Limited (LSF) ORDINARY FULLY PAID |
Financials |
$1,736 |
Net Tangible Asset Backing
|
26 Nov 2024 8:28AM |
$3.040 |
$2.760 |
fallen by
9.21%
|
|
| NobleOak Life Limited (NOL) ORDINARY FULLY PAID |
Financials |
$126 |
2024 AGM - Chair and CEO Addresses
|
26 Nov 2024 8:28AM |
$1.675 |
$1.355 |
fallen by
19.10%
|
|
Goals & planningInvesting goal hubsSaving to build wealth
Saving for happy retirement 
Call 1300 880 160
Start a chat
Schedule a call
